Abstract
The inventions relate to compounds and compositions comprising connexin modulators and their use in dose regimens for the treatment of non-healing or persistent ocular surface or corneal defects and disorders.
Full Text
What is claimed is:
The inventions relate to compounds and compositions comprising connexin modulators and their use in dose regimens for the treatment of non-healing or persistent ocular surface or corneal defects and disorders.
Timeline
Filed
05/22/2026Published
09/17/2026Granted
Not AvailableIPC Codes(6)
A61K 31/7125:Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 47/10:Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers